Nadia Daizadeh

4.3k total citations · 2 hit papers
84 papers, 2.1k citations indexed

About

Nadia Daizadeh is a scholar working on Oncology, Physiology and Immunology. According to data from OpenAlex, Nadia Daizadeh has authored 84 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 27 papers in Physiology and 24 papers in Immunology. Recurrent topics in Nadia Daizadeh's work include Asthma and respiratory diseases (27 papers), Bone health and osteoporosis research (23 papers) and Bone health and treatments (20 papers). Nadia Daizadeh is often cited by papers focused on Asthma and respiratory diseases (27 papers), Bone health and osteoporosis research (23 papers) and Bone health and treatments (20 papers). Nadia Daizadeh collaborates with scholars based in United States, Canada and France. Nadia Daizadeh's co-authors include Rachel B. Wagman, David L. Kendler, Socrates E. Papapoulos, Kurt Lippuner, Henry G. Bone, Maria Luisa Brandi, E. J. Czerwiński, Christian Roux, Andrea Wang and Jacques P. Brown and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Journal of Bone and Joint Surgery.

In The Last Decade

Nadia Daizadeh

79 papers receiving 2.1k citations

Hit Papers

10 years of denosumab treatment in postmenopausal women w... 2017 2026 2020 2023 2017 2022 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
    2017 662 citations Henry G. Bone, Rachel B. Wagman et al. profile →
  2. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis
    2022 146 citations Amr Radwan, Nadia Daizadeh et al. The Journal of Allergy and Clinical Immunology In Practice profile →

Peers

Nadia Daizadeh
S. Niemi Finland
Laëtitia Michou Canada
G. Kollerup Denmark
P.W.P. Bearcroft United Kingdom
Roland Kocijan Austria
Richard W. Nicholas United States
M D Fallon United States
Carlo Bernasconi Italy
Richard Newmark United States
Kristina Forslind Sweden
S. Niemi Finland
Nadia Daizadeh
Citations per year, relative to Nadia Daizadeh Nadia Daizadeh (= 1×) peers S. Niemi

Countries citing papers authored by Nadia Daizadeh

Since Specialization
Citations

This map shows the geographic impact of Nadia Daizadeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadia Daizadeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadia Daizadeh more than expected).

Fields of papers citing papers by Nadia Daizadeh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadia Daizadeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadia Daizadeh. The network helps show where Nadia Daizadeh may publish in the future.

Co-authorship network of co-authors of Nadia Daizadeh

This figure shows the co-authorship network connecting the top 25 collaborators of Nadia Daizadeh. A scholar is included among the top collaborators of Nadia Daizadeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadia Daizadeh. Nadia Daizadeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Izem, Rima, Emmanuel Zuber, Nadia Daizadeh, et al.. (2024). Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework. Therapeutic Innovation & Regulatory Science. 58(3). 495–504. 7 indexed citations
2.
Papadopoulos, Nikolaos G., Stanley J. Szefler, Leonard B. Bacharier, et al.. (2023). Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma. Allergy. 78(8). 2157–2167. 16 indexed citations
3.
Corren, Jonathan, David J. Jackson, Thomas B. Casale, et al.. (2023). Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization. Journal of Asthma and Allergy. Volume 16. 249–260. 4 indexed citations
4.
Hanania, Nicola A., Mario Castro, Eric D. Bateman, et al.. (2022). Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Annals of Allergy Asthma & Immunology. 130(2). 206–214.e2. 8 indexed citations
5.
Domingo, Christian, Jorge Máspero, Mario Castro, et al.. (2022). Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. The Journal of Allergy and Clinical Immunology In Practice. 10(7). 1835–1843. 11 indexed citations
6.
Kühle, Jens, Nadia Daizadeh, Pascal Benkert, et al.. (2021). Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS. Multiple Sclerosis Journal. 28(4). 573–582. 26 indexed citations
7.
Papi, Alberto, Mario Castro, Jonathan Corren, et al.. (2021). LONG-TERM EFFECT OF DUPILUMAB ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 ASTHMA: LIBERTY ASTHMA TRAVERSE STUDY. CHEST Journal. 160(4). A1854–A1858. 1 indexed citations
8.
9.
Steingo, Brian, Yaser Al Malik, Ann Bass, et al.. (2020). Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. Journal of Neurology. 267(11). 3343–3353. 41 indexed citations
10.
11.
Oreja‐Guevara, Celia, Raed Alroughani, David Brassat, et al.. (2017). Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study). Queensland's institutional digital repository (The University of Queensland). 1 indexed citations
12.
Adachi, Jonathan D., Henry G. Bone, Nadia Daizadeh, et al.. (2017). Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. BMC Musculoskeletal Disorders. 18(1). 174–174. 11 indexed citations
13.
Ferrari, Serge, S. Adámi, Jacques P. Brown, et al.. (2016). relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment. Open Repository and Bibliography (University of Liège). 1 indexed citations
14.
Ferrari, Serge, Cesar Libanati, S. Adámi, et al.. (2015). Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment. Open Repository and Bibliography (University of Liège). 5 indexed citations
15.
Papapoulos, Socrates E., Kurt Lippuner, Christian Roux, et al.. (2015). The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporosis International. 26(12). 2773–2783. 203 indexed citations
16.
Papapoulos, Socrates E., Kurt Lippuner, C. Roux, et al.. (2014). EIGHT YEARS OF DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST FIVE YEARS OF THE FREEDOM EXTENSION. Open Repository and Bibliography (University of Liège). 12 indexed citations
17.
Grbic, John T., et al.. (2014). Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated with Denosumab. Results from the Pivotal Phase 3 Fracture Study Extension. Data Archiving and Networked Services (DANS). 66. 3 indexed citations
18.
Bone, Henry G., R. Chapurlat, Cesar Libanati, et al.. (2011). Safety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis. Open Repository and Bibliography (University of Liège). 3 indexed citations
19.
Papapoulos, Socrates E., Z. Man, Dan Mellström, et al.. (2011). FIVE-YEAR DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST TWO YEARS OF THE FREEDOM TRIAL EXTENSION. Data Archiving and Networked Services (DANS). 9 indexed citations
20.
Chapurlat, R., Socrates E. Papapoulos, Henry G. Bone, et al.. (2010). Long-term denosumab treatment of postmenopausal women with osteoporosis: results from the first year extension study of the FREEDOM trial. Open Repository and Bibliography (University of Liège). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Niemi Breakdown of academic impact, for papers by Laëtitia Michou Breakdown of academic impact, for papers by G. Kollerup Breakdown of academic impact, for papers by P.W.P. Bearcroft Breakdown of academic impact, for papers by Roland Kocijan Breakdown of academic impact, for papers by Richard W. Nicholas Breakdown of academic impact, for papers by M D Fallon Breakdown of academic impact, for papers by Carlo Bernasconi Breakdown of academic impact, for papers by Richard Newmark Breakdown of academic impact, for papers by Kristina Forslind
Rankless by CCL
2026